title: Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
abstract: The specific thrombin inhibitor r-hirudin (HBW 023) has been demonstrated to be effective in preventing thrombosis in preclinical models. Up to now, no bleeding complications have been observed using therapeutically effective doses in animals studies. However, in case of inadvertent overdosing the occurrence of undesired impairment of coagulation cannot be excluded. As a potential antidote an activated prothrombin complex concentrate (APC) was tested on its ability to normalize blood coagulation. APC given s bolus injections 5 min and 3.0 mg/kg neutralized the r-hirudin-induced prolongation and 3.0 mg/kg neutralized the r-hirudin-induced prolongation of whole blood coagulation time in rabbits completely within 5 min without any clot formation in the blood vessels or capillaries of the heart, kidneys, or lungs. Furthermore, bleeding time prolongation induced by bolus application of 3.0 and 30.0 mg/kg r-hirudin was significantly inhibited by APC within 5 min. These results suggest that administration of APC may be an effective way to reverse the effects of r-hirudin in the coagulation system in case of inadvertent overdosing of r-hirudin.
authors.affiliation: Research Laboratories of Behringwerke AG, Marburg/Lahn, Germany.
authors.forename: K H
authors.initials: KH
authors.lastname: Diehl
authors.forename: J
authors.initials: J
authors.lastname: Römisch
authors.forename: B
authors.initials: B
authors.lastname: Hein
authors.forename: A
authors.initials: A
authors.lastname: Jessel
authors.forename: H
authors.initials: H
authors.lastname: Ronneberger
authors.forename: E P
authors.initials: EP
authors.lastname: Pâques
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000378:metabolism*; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006629:Hirudins / Q000037:antagonists & inhibitors* / Q000506:poisoning; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D014914:Whole Blood Coagulation Time
chemical_list: D000991:Antithrombins; D001779:Blood Coagulation Factors; D006629:Hirudins; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates